Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy
NCT00749138 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2010-03-09
Summary
A short 14 day phase 1 study examining 6 monotherapy doses of oral tamoxifen for safety in chronic HCV patients who have failed standard treatment of peginterferon and ribavirin.
Conditions
- Chronic Hepatitis C
Interventions
- DRUG
-
tamoxifen
giving drug tamoxifen
Sponsors & Collaborators
-
Bader, Ted, M.D.
lead INDIV
Principal Investigators
-
Ted Bader · OUHSC
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-11-30
- Primary Completion
- 2009-05-31
- Completion
- 2009-10-31
Countries
- United States
Study Locations
More Related Trials
-
Efficacy of a 12-Week Regimen of Telaprevir, Pegylated Interferon, and Ribavirin in Treatment-Naive and Prior Relapser Subjects With Interleukin28B (IL28B) CC Genotype
NCT01459913 ·Status: TERMINATED ·Phase: PHASE3
-
A Study of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Sofosbuvir and Ribavirin in Direct-Acting Antiviral Agent Treatment-Experienced Adults With Chronic Hepatitis C Virus Infection
NCT02356562 ·Status: COMPLETED ·Phase: PHASE2
-
TMC435-TiDP16-C114 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC435 and the Antiretroviral Agents TMC278 and Tenofovir
NCT01205139 ·Status: COMPLETED ·Phase: PHASE1
-
TMC649128HPC1002 - a Trial inGenotype 1 Hepatitis C Virus (HCV) - Infected Participants to Determine the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of TMC649128, Alone and Combined With Pegylated Interferon + Ribavirin
NCT01391117 ·Status: TERMINATED ·Phase: PHASE1
-
An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
NCT01513941 ·Status: COMPLETED ·Phase: PHASE3
-
TMC435-TiDP16-C113: A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics of TMC435
NCT01046058 ·Status: COMPLETED ·Phase: PHASE1
-
Safety, Antiviral Activity and PK of MRD of BI 201335 in Chronic Hepatitis C Patients Both Treatment Naive and -Experienced
NCT00793793 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluating the Safety and Efficacy of Inarigivir in Non-cirrhotic Treatment Naive Subjects Infected With Hepatitis B Virus
NCT04059198 ·Status: TERMINATED ·Phase: PHASE2
-
Thalidomide Plus Peginterferon and Ribavirin in Patients With Interferon Resistance
NCT00856804 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of the Pharmacokinetic Action of Amantadine and Ribavirin in Chronic Hepatitis C. CINAM
NCT00199719 ·Status: COMPLETED ·Phase: PHASE2
-
Effectiveness, Safety and Clinical Outcomes of Paritaprevir/Ombitasvir/r+Dasabuvir 8 Weeks
NCT03122132 ·Status: COMPLETED
-
Long Term Extension Study is Designed to Monitor Long-Term Efficacy and Safety of Miravirsen Sodium in Combination With Telaprevir and Ribavirin in Subjects With Chronic Hepatitis C Virus Genotype 1 Infection
NCT02452814 ·Status: COMPLETED
-
A Study Evaluating 24-Week and 48-Week Telaprevir-Based Regimen in Treatment Naïve Subjects With Genotype 1 Chronic Hepatitis C Who Achieve an Extended Rapid Viral Response
NCT00758043 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluating the Safety of ITX 5061 in Treatment-Naive Hepatitis C (HCV)-Infected Adults
NCT01165359 ·Status: COMPLETED ·Phase: PHASE1
-
Hepatitis C Rimantadine and Antiviral Combination Therapy
NCT01413490 ·Status: COMPLETED
-
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
NCT02717949 ·Status: TERMINATED ·Phase: PHASE4
-
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection
NCT05763576 ·Status: TERMINATED ·Phase: PHASE1
-
High-Dose Ribavirin and Peginterferon to Treat Chronic Hepatitis C Genotype 1
NCT00735969 ·Status: COMPLETED ·Phase: PHASE2
-
Boceprevir/PegIFN α-2b/Riba in HCV+ Gt1 Menopausal Women, Nonresponders to PegIFN/Riba or Treatment-naives (MEN_BOC)
NCT01457937 ·Status: UNKNOWN ·Phase: PHASE3
-
Drug Drug Interaction Study Between BI 201335 and BI 207127 in Chronic Hepatitis C Infected Patients
NCT01525628 ·Status: COMPLETED ·Phase: PHASE1
-
Viral Kinetics and Liver Gene Expression in Response to Ribavirin and Peginterferon Therapy of Chronic Hepatitis C
NCT00718172 ·Status: COMPLETED ·Phase: PHASE1
-
A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4)
NCT00959699 ·Status: COMPLETED ·Phase: PHASE2
-
Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults
NCT00100581 ·Status: COMPLETED ·Phase: NA
-
Ribavirin Dose Optimization for the Treatment of Hepatitis C
NCT01289496 ·Status: COMPLETED ·Phase: PHASE2
-
CPG10101 Combination Therapy For The Treatment Of Hepatitis C In Relapsed Hepatitis C Virus (HCV) Subjects
NCT00142103 ·Status: COMPLETED ·Phase: PHASE1